Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAZOGLIO: Pazopanib + Temozolomide in Newly Diagnosed Glioblastoma
NCT02331498Phase 2Active, not recruiting
- Sponsor
- Centre Antoine Lacassagne
- Start
- Jun 2015
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in glioblastoma multiforme (GBM), sponsored by Centre Antoine Lacassagne. Started Jun 2015; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02331498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331498.